Abstract Frequent allelic losses within chromosomal band 17q25
Introduction
Human cancers derived from breast, esophagus, and ovary frequently show allelic losses on the long arm of chromosome 17 (Fukino et al. 1999; Kalikin et al. 1996; Saito et al. 1993) . Putative tumor suppressor genes on 17q are postulated as targets of these events. BRCA1, known primarily as the site of inherited mutations that confer predisposition to breast cancers, was initially considered to be the target of 17q deletions in sporadic cases also, because it is located at 17q21, where loss of heterozygosity (LOH) is common. However, inactivating mutations within the BRCA1 gene do not appear to play a major role in the development of sporadic breast cancers. Therefore, regions of 17q other than the BRCA1 locus may be targets of LOH in those tumors.
A locus linked to hereditary focal nonepidermolytic palmoplantar keratoderma, a condition associated with cancer of the esophagus, lies on 17q25.1 (Kelsell et al. 1996) ; this esophageal-cancer susceptibility locus, TOC (tylosis with oesophageal cancer), could be a target of 17q deletion in other types of malignancy as well (Kalikin et al. 1996) . We ourselves have defined a commonly deleted region in breast cancers within the 1-cM interval between D17S1603 and D17S1839 on chromosome 17q25.1 (Fukino et al. 1999) . However, the genetic locus for TOC has recently been mapped to an equally narrow region flanked by D17S1839 and D17S785 (Risk et al. 1999 ) that is immediately adjacent to the segment we defined in breast cancers. These observations make it highly likely that the 17q25.1 region contains more than one tumor suppressor gene.
Here we describe the identification of a novel cDNA derived from chromosomal segment 17q25.1. Using the reverse transcriptase-polymerase chain reaction (RT-PCR) we found loss, or extreme decrease, of expression of this gene in 26 of 56 cancer cell lines derived from tumors that arose in various tissues. The 3293-bp full-length cDNA encodes a 788-amino-acid product with the characteristics of an integral membrane protein. As the gene showed loss of expression in multiple types of human cancers, we named it DMC1 ("downregulated in multiple cancers-1").
Materials and methods
Cloning strategy to identify genes with altered expression
We obtained information concerning expressed-sequence tags (ESTs) in the relevant region (D17S1352 to D17S785 on 17q25) from the human GeneMap 99 and from the Whitehead Institute Genome Database, purchased the appropriate clones from Genome Systems (St. Louis, MO, USA), and verified their sequences. We then examined each transcript for altered expression in our cancer cell lines by means of semi-quantitative RT-PCRs, using published primer sets.
Cell culture
The 56 cancer cell lines analyzed were derived from 10 breast cancers (MDA-MB-453, CRL1500, YMB-1-E, MCF7, HBL100, OCUB-M, BT-20, BT-474, MDA-MB-435S, and SK-BR-3), 10 uterine cancers (SIHA, HT-3, D98-AH-2, HeLaTG, HeLa, CaSki, ME-180, HeLaP3, HEC1-A, and SK-UT-1B), 13 hepatocellular carcinomas (SK-HEP-1, C-HC-4, Hep-KANO CL-2, WRL68, Chang liver, Hep-TABATA, HuH7, Hep G2, HT17, Li7, PLC/PRF/5, Hep3b, and C3A), 7 lung cancers (RERF-LC-AI, LU65, Lu99, PC14, A549, EBC-1, and LK-2), 6 thyroid cancers (WRO, NPA, 8305c, ARO, FRO, and 8505c), 4 renal-cell cancers (OS-RC-2, VMRC-RCW, RCC10RB, and Caki-1), and 6 gastric cancers (HuGC-OOHIRA, AZ521, H-111-TC, SH-10-TC, . The cell lines were either donated by the Cell Resource Center for Biomedical Research at the Institute of Development, Aging, and Cancer of Tohoku University, or by Dr. Baba at Mie University, or they were purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA). Each cell line was cultured in the optimized conditions recommended by the respective distributor.
DNA and RNA extraction and reverse transcription (RT) DNA was extracted from the cell lines by phenolchloroform procedures described previously . Total RNA was extracted using a detergent reagent, following the procedures described elsewhere (Kitamura et al. 1999) . Each mRNA was prepared from 1 ϫ 10 8 cells by the oligo-dT cellulose method (FastTrack 2.0 Kit; Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Reverse transcription reactions were carried out using the SMART RACE cDNA amplification kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions.
Northern-blot analysis of DMC1
PolyA RNA-blotted membranes prepared from various normal human tissues were obtained from Clontech. We followed the technique recommended in the Clontech manual for Northern analysis with EST stSG2564, as well as full-length DMC1 cDNA as probe.
Polymerase chain reactions and RT-PCR PCR amplifications were performed for 27 cycles in 30-µl reaction volumes containing 10pmol of each primer, 1 ϫ PCR buffer with 1.5mM MgCl2, and 0.5 units of Taq DNA polymerase, conditions that we empirically determined to enable comparison of gene expression levels. PCR products were stained with ethidium bromide after electrophoresis in agarose gels. Thermocycling conditions for amplification were described previously Watanabe et al. 1998) . To quantify relative expression levels among the cell lines, we carried out duplex PCRs with G3PDH primers (forward, 5Ј-ACCACAGTCCATGCCA TCAC-3Ј; reverse, 5Ј-TCCACCACCCTGTTGCTGTA-3Ј).
Single-strand conformational polymorphism (SSCP) analysis by silver staining
The coding region of DMC1 cDNA was divided into 11 amplicons that overlapped their flanking segments by short sequences. Each segment was amplified by PCR; then, about 10 ng of each PCR product was heat-denatured in the presence of 80% of deionized formamide and electrophoresed in an 8% polyacrylamide gel, with or without 10% glycerol in 0.5 ϫ tris-borate/EDTA (TBE), at 8V/cm for 10h at room temperature (Hirayama et al. 1998) . DNA fragments were visualized by silver staining, as described previously (Hoshino et al. 1992 ).
Sequence determination
Nucleotide sequences were determined by the BigDye (PE Applied Biosystems, Foster, CA, USA) Terminator cyclesequencing method, using an auto-sequencer (ABI PRISM 377; PE Applied Biosystems, Foster, CA, USA).
Results
Transcript of downregulated gene at 17q25.1 Among ESTs from an interval flanked by D17S1352 and D17S785 at 17q25, a region that is commonly deleted in breast cancers (Fukino et al. 1999 ) and in esophageal cancers (Risk et al. 1999) , one transcribed sequence (stSG2564; GenBank accession no. Z395239) showed loss of expression in multiple cell lines derived from various cancer types. To examine the expression pattern and determine the size of the complete transcript, we hybridized this EST probe to a multiple-tissue Northern blot (Clontech). The 3.8-kb transcript ( Fig. 1 ) was expressed ubiquitously, except for thymus and peripheral blood lymphocytes, and was most abundant in placenta and brain. The transcript observed in brain was slightly longer than that in other tissues, suggesting the existence of a splicing variant or the use of an alternative polyadenylation site in brain tissue. Northern hybridization carried out later with the full-length cDNA as probe revealed essentially the same profile (data not shown).
Cloning full-length cDNA for DMC1
To clone the full-length cDNA for the novel gene that we named "DMC1" (downregulated in multiple cancers-1), we used EST stSG2564 to screen a full-length-enriched cDNA library that had been constructed by means of oligocapping, using mRNA derived from colonic mucosa (Maruyama and Sugano 1994; Suzuki et al. 1997) . Positive clones isolated from this library showed sequence identity with stSG2564 within their 3Ј-untranslated regions. Sequencing of these clones revealed that the longest representative cDNA, HUV00353, contained an insert 3293 bp long. Its open reading frame (ORF), nucleotides 79 to 2442, encoded a protein of 788 amino acids (Fig. 2) . Because the sequence surrounding the initiation codon agrees with the Kozak rule (Kozak 1984) , this methionine most likely represents the transcription start site.
Structural features of the DMC1 protein
The TMpred program (http://dot.imgen.bcm.tmc.edu:9331/ seq-search/struc-predict.html) predicted that the DMC1 product would be an integral membrane protein of the socalled "inside-out" type; its single transmembrane domain corresponds to amino acid residues 245 to 268 (see Fig. 2 ). It lacks a signal sequence but possesses an N-terminal cytoplasmic domain and a C-terminal extracellular domain. A basic local alignment search tool (BLAST) search found significant amino-acid homology (26% identical and 45% positive) with a hypothetical 104.8-kD protein from Schizosaccharomyces pombe (GenBank accession no. O13776). Part of the DMC1 cDNA showed similarity with an archived cDNA, DKFZp434I1120 (GenBank accession no. AL137556), although the latter lacks the 1074-bp of sequence in the 3Ј region, and its encoded product contains an insertion of Trp at codon 130 and a substitution of Leu for Pro at codon 352.
Expression of DMC1 in cancer cell lines and sequence variations
We examined the expression of DMC1 in 56 cancer cell lines. RT-PCR experiments showed loss of expression of this gene in 2 of 10 breast-cancer lines, in 7 of 10 uterinecancer lines, in 7 of 13 hepatocellular-cancer lines, in 3 of 7 lung-cancer lines, in 3 of 6 thyroid-cancer lines, in 2 of 6 gastric-cancer lines, and in 2 of 4 renal cell-cancer lines. We confirmed these results by semi-quantitative RT-PCR, using as an internal control the housekeeping gene G3PDH. That analysis demonstrated loss or dramatic attenuation of expression of DMC1 in many cell lines (for examples, see Fig. 3 ).
To search for sequence variations in DMC1 we amplified the full-length coding region of DMC1 mRNA in each of 41 tumor cell lines. The RT-PCR products were screened for variations using SSCP analysis, followed by visualization with silver staining. RT-PCR products with potential variations were sequenced directly with automated instruments. By comparing normal tissues with cancer cell lines, we observed two silent polymorphisms within the coding region of DMC1. The first, cytosine/thymine, was located at the third nucleotide of codon 316 (Ala); the allelic frequencies were 0.62 for C and 0.38 for T. The second polymorphism, again cytosine/thymine, involved the third nucleotide of codon 502 (Thr); frequencies were 0.96 (C) and 0.04 (T). As both variations were observed in normal samples, neither represented a somatic mutation.
Discussion
Sporadic cancers of the breast, esophagus, and ovary have often shown allelic losses on the long arm of chromosome 17. Three or four distinct regions of deletion on 17q have been identified in sporadic breast cancers (Cropp et al. 1993; Nagai et al. 1994; Kalikin et al. 1996; Niederacher et al. 1997; Plummer et al. 1997) . Mutations of the BRCA1 gene at 17q21 are responsible for predisposition to a hereditary syndrome of breast/ovarian cancer. Moreover, the TOC (tylosis oesophageal cancer) locus associated with focal nonepidermolytic palmoplantar keratoderma, an autosomal dominant disorder of keratinization that is frequently associated with esophageal cancer, lies between markers AFMb054zf9 (D17S1839) and D17S1603 at 17q25.1 (Risk et al. 1994; Kelsell et al. 1996) . We previously examined both of these loci in 178 primary breast cancers (Fukino et al. 1999) , and observed allelic losses in 97 (55%) of these tumors. Losses were most frequent at markers around the TOC locus (48% at D17S1839 and 43% at D17S1603), where we identified a distinct commonly deleted region within a 1-cM interval. Another larger but separate commonly deleted region, including the BRCA1 gene, exhibited allelic loss at D17S934 in 45% of the breast cancers examined. Therefore BRCA1 and TOC appear to be independent targets of allelic loss on 17q in primary breast cancers, and inactivation of the TOC locus in particular may play an important role in the genesis of sporadic breast tumors. However, large-scale sequencing efforts around the TOC locus within 17q25.1, aided by the Human Genome Project, have not, as yet, resulted in the discovery of a classical (class I) tumor suppressor gene that shows frequent mutations or deletions in human cancers (Zou et al. 1994) .
Two known genes in the 17q25.1 region, EVPL and TK1, can be considered candidates for palmoplantar keratoderma (PPK)/TOC Ruhrberg et al. 1996) . EVPL encodes envoplakin, which belongs to the family of keratin-binding proteins; its alteration may be associated with keratinocyte dysfunction . TK1 encodes a soluble thymidine kinase whose abnormal expression has been observed in several malignancies, including breast cancer (Ruhrberg et al. 1996) .
The present study has revealed loss of expression of a novel gene from this region, DMC1, in a large portion of the human cancer cell lines we examined. Genes that frequently show decreased expression in tumors are characterized as class II tumor suppressors (Zou et al. 1994) . Our results suggest that DMC1 might belong to class II, because of its location in the TOC region, the loss of expression in multiple cancer cell lines, and the absence of detectable mutations of DMC1 in these specimens. Although no class I tumor suppressor has yet been identified from the 17q25.1 region, it is attractive to speculate that regional inactivation of multiple genes from this chromosomal band contributes to tumor formation (Zou et al. 1994 ). The 17q25.1 region shows frequent LOH in a number of different cancer types, such as breast, esophageal, and ovarian tumors. However, because our mutational analysis has shown that DMC1 is not a mutational target, it is apparently inactivated by other mechanisms (e.g., allelic loss, methylation, or even haploinsufficiency). Future studies that include functional analysis of this gene through transfection to cancer cells, or methylation analysis once the promoter region is identified, would help to clarify these issues.
The majority of "inside-out" membrane proteins are cell surface-receptor or ligand proteins. These include CD40L (Hollenbaugh et al. 1992) , CD26 (Hegen et al. 1990; Tanaka et al. 1992) , CD23 (Ikuta et al. 1987; Ludin et al. 1987) , NKR-P1 (Yokoyama and Seaman 1993) , and FasL (Suda et al. 1993) . DMC1 has the "Pro-Pro-X-Pro" motif near the transmembrane domain. This motif was found to be conserved among receptors for cytokines, such as interleukin-3 receptor (IL-3R)α, granulocyte macrophage-colony stimulating factor receptor (GM-CSFR)α, prolactin receptor, and growth hormone receptor (Miyajima et al. 1992) . Thus, we speculate that DMC1 functions as a receptor protein for cytokines or other related peptides.
